International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

Mateos, M.V. (María Victoria); Kumar, S. (Shaji); Dimopoulos, M.A. (Meletios A.); Gonzalez-Calle, V. (Veronica); Kastritis, E. (Efstathios); Hajek, R. (R.); De-Larrea, C.F. (Carlos Fernández); Morgan, G.J. (Gareth J.); Merlini, G. (G.); Goldschmidt, H. (Hartmut); Geraldes, C. (Catarina); Gozzetti, A. (A.); Kyriakou, C. (Charalampia); Garderet, L. (Laurent); Hansson, M. (Markus); Zamagni, E. (Elena); Fantl, D. (Dorotea); Leleu, X. (Xavier); Kim, B.S. (Byung-Su); Esteves, G. (Graça); Ludwig, H. (Heinz); Usmani, S.Z. (Saad Z.); Min, C.K. (Chang-Ki); Qi, M. (Ming); Ukropec, J. (Jon); Weiss, B.M. (Brendan M.); Rajkumar, S.V. (S. Vincent); Durie, B. (B.); San-Miguel, J.F. (Jesús F.)

Issue Date:

2020

ISSN:

2044-5385

Editorial note:

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Note:

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Citation:

Mateos, M.V. (María Victoria); Kumar, S. (Shaji); Dimopoulos, M.A. (Meletios A.); et al. "International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)". Blood Cancer Journal. 10 (102), 2020,

Abstract

Smoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR: 2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2–3 factors). Addition of cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1, intermediate risk with 2, and high risk with ≥3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years, respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical research and routine practice and will be widely applicable.

URI:

https://hdl.handle.net/10171/66694

DOI:

10.1038/s41408-020-00366-3

Appears in Collections:

DA - CIMA - Hemato-oncología - Mieloma - Artículos de Revista

Files in This Item: